Inge Jedema

3.3k citations

80 papers · 1.9k · h-index 26

Impact in

Hematology top 1%
- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
Immunology top 2%
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- T-cell and B-cell Immunology

Papers in

Immunology 42
- T-cell and B-cell Immunology 24
- Immune Cell Function and Interaction 24
- Immunotherapy and Immune Responses 19
Hematology 29
- Hematopoietic Stem Cell Transplantation 23
- Acute Myeloid Leukemia Research 5

Co-authors: J.H. Frederik Falkenburg (57 shared papers)Roel Willemze (16 shared papers)Renée M. Y. Barge (8 shared papers)Mirjam H.M. Heemskerk (16 shared papers)Michel G.D. Kester (12 shared papers)Jacques J. M. van Dongen (2 shared papers)Marieke Griffioen (9 shared papers)Vincent H. J. van der Velden (2 shared papers)
Journals: Blood (15 papers)Frontiers in Immunology (6 papers)Leukemia (6 papers)Haematologica (4 papers)Biology of Blood and Marrow Transplantation (4 papers)
Partner nations: Netherlands United States Germany

In The Last Decade

Inge Jedema

80 papers receiving 1.9k citations

Peers

Countries citing papers authored by Inge Jedema

Since Specialization

Citations

This map shows the geographic impact of Inge Jedema's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Inge Jedema with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Inge Jedema more than expected).

Fields of papers citing papers by Inge Jedema

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Inge Jedema. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Inge Jedema. The network helps show where Inge Jedema may publish in the future.

Co-authors

The 25 scholars most cited alongside Inge Jedema, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Inge Jedema Line = papers co-authored together Inge Jedema links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 80 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population Blood ·Inge Jedema, Nicole M. van der Werff, Renée M. Y. Barge, Roel Willemze, J.H. Frederik Falkenburg	2003	145
2	Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia Journal of Clinical Investigation ·Dyantha I. van der Lee, Rogier M. Reijmers, Maria W. Honders, Renate S. Hagedoorn, Rob C. M. de Jong, Michel G.D. Kester, Dirk M. van der Steen, Arnoud H. de Ru, Christiaan Kweekel, Helena M. Bijen, Inge Jedema, Hendrik Veelken, Peter A. van Veelen, Mirjam H.M. Heemskerk, J.H. Frederik Falkenburg, Marieke Griffioen	2019	130
3	Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity Leukemia ·Inge Jedema, Renée M. Y. Barge, Vincent H. J. van der Velden, Bart Nijmeijer, Jacques J. M. van Dongen, Roel Willemze, J.H. Frederik Falkenburg	2003	119
4	High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg®) treatment in acute myeloid leukemia patients Leukemia ·Vincent H. J. van der Velden, Nancy Boeckx, Inge Jedema, J G te Marvelde, Patricia G. Hoogeveen, M. Boogaerts, Jacques J. M. van Dongen	2004	99
5	PRAME-Specific Allo-HLA–Restricted T Cells with Potent Antitumor Reactivity Useful for Therapeutic T-Cell Receptor Gene Transfer Clinical Cancer Research ·Avital L. Amir, Dirk M. van der Steen, Marleen M. van Loenen, Renate S. Hagedoorn, Renate de Boer, Michel D.G. Kester, Arnoud H. de Ru, Gertjan Lugthart, Cees van Kooten, Pieter S. Hiemstra, Inge Jedema, Marieke Griffioen, Peter A. van Veelen, J.H. Frederik Falkenburg, Mirjam H.M. Heemskerk	2011	96
6	Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response Journal of Clinical Investigation ·Cornelis A.M. van Bergen, Simone A.P. van Luxemburg-Heijs, Liesbeth C. de Wreede, Matthijs Eefting, Peter A. von dem Borne, Peter van Balen, Mirjam H.M. Heemskerk, Arend Mulder, F. Claas, Marcelo A. Navarrete, Wilhelmina M. Honders, Caroline E. Rutten, Hendrik Veelken, Inge Jedema, Constantijn J.M. Halkes, Marieke Griffioen, J.H. Frederik Falkenburg	2017	81
7	BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells Cancer Research ·Sarah E. Alford, Anisha Kothari, Floris C. Loeff, Joshua M. Eichhorn, Nandini Sakurikar, Henriëtte M. Goselink, Robert L. Saylors, Inge Jedema, J.H. Frederik Falkenburg, Timothy C. Chambers	2015	74
8	HLA class II upregulation during viral infection leads to HLA-DP–directed graft-versus-host disease after CD4+ donor lymphocyte infusion Blood ·Sanja Stevanović, Cornelis A.M. van Bergen, Simone A.P. van Luxemburg-Heijs, Boris van der Zouwen, Ekaterina S. Jordanova, Alwine B. Kruisselbrink, Marian van de Meent, Jessica C. Harskamp, Frans H.J. Claas, Erik W.A. Marijt, Jaap Jan Zwaginga, Constantijn J.M. Halkes, Inge Jedema, Marieke Griffioen, J.H. Frederik Falkenburg	2013	64
9	Multiple myeloma–reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene Blood ·Cornelis A.M. van Bergen, Michel G.D. Kester, Inge Jedema, Mirjam H.M. Heemskerk, Simone A.P. van Luxemburg-Heijs, Freke M. Kloosterboer, W. A. Erik Marijt, Arnoud H. de Ru, M. Ron Schaafsma, Roel Willemze, Peter A. van Veelen, J.H. Frederik Falkenburg	2007	61
10	Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer Blood ·Elisabeth H. Slager, M. Willy Honders, Edith D. van der Meijden, Simone A.P. van Luxemburg-Heijs, Freke M. Kloosterboer, Michel G.D. Kester, Inge Jedema, W. A. Erik Marijt, M. Ron Schaafsma, Roel Willemze, J.H. Frederik Falkenburg	2006	53
11	Effective Treatment of Refractory CMV Reactivation After Allogeneic Stem Cell Transplantation With In Vitro-generated CMV pp65-specific CD8+ T-cell Lines Journal of Immunotherapy ·Pauline Meij, Inge Jedema, Maarten L. Zandvliet, Pim L. J. van der Heiden, Marian van de Meent, H. M. Esther van Egmond, Ellis van Liempt, Conny Hoogstraten, Simone Kruithof, Sabrina A.J. Veld, Erik W.A. Marijt, Peter A. von dem Borne, Arjan C. Lankester, Constantijn J.M. Halkes, J.H. Frederik Falkenburg	2012	48
12	HLA-DP as specific target for cellular immunotherapy in HLA class II-expressing B-cell leukemia Leukemia ·Caroline E. Rutten, Simone A.P. van Luxemburg-Heijs, Marieke Griffioen, Erik W.A. Marijt, Inge Jedema, Mirjam H.M. Heemskerk, E.F.M. Posthuma, Roel Willemze, JH Falkenburg	2008	45
13	Generation and administration of HA-1-specific T-cell lines for the treatment of patients with relapsed leukemia after allogeneic stem cell transplantation: a pilot study Haematologica ·Pauline Meij, Inge Jedema, Menno A. W. G. van der Hoorn, R. Bongaerts, Laura A. Cox, Amon R. Wafelman, Erik W.A. Marijt, Rein Willemze, J.H. Frederik Falkenburg	2012	42
14	Myeloid leukemic progenitor cells can be specifically targeted by minor histocompatibility antigen LRH-1–reactive cytotoxic T cells Blood ·Wieger J. Norde, Ingrid M. Overes, Frans Maas, Hanny Fredrix, Johanna C. M. Vos, Michel G.D. Kester, Robbert van der Voort, Inge Jedema, J.H. Frederik Falkenburg, A Schattenberg, Theo M. de Witte, Harry Dolstra	2008	38
15	A Good Manufacturing Practice procedure to engineer donor virus-specific T cells into potent anti-leukemic effector cells Haematologica ·Marleen M. van Loenen, Renate de Boer, Ellis van Liempt, Pauline Meij, Inge Jedema, J.H. Frederik Falkenburg, Mirjam H.M. Heemskerk	2013	37
16	Expression of co‐stimulatory and adhesion molecules and chemokine or apoptosis receptors on acute myeloid leukaemia: high CD40 and CD11a expression correlates with poor prognosis British Journal of Haematology ·Rolf E. Brouwer, Juliette J. Hoefnagel, Boudewijn Borger Van Der Burg, Inge Jedema, Koos Zwinderman, Ingrid Starrenburg, Hanneke C. Kluin‐Nelemans, Renée M. Y. Barge, Roel Willemze, J.H. Frederik Falkenburg	2001	35
17	Simultaneous Isolation of CD8+ and CD4+ T Cells Specific for Multiple Viruses for Broad Antiviral Immune Reconstitution After Allogeneic Stem Cell Transplantation Journal of Immunotherapy ·Maarten L. Zandvliet, Ellis van Liempt, Inge Jedema, Simone Kruithof, Michel G.D. Kester, Henk‐Jan Guchelaar, J.H. Frederik Falkenburg, Pauline Meij	2011	35
18	Graft versus tumor effects and why people relapse Hematology ·J.H. Frederik Falkenburg, Inge Jedema	2017	34
19	HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study Frontiers in Immunology ·Peter van Balen, Inge Jedema, Marleen M. van Loenen, Renate de Boer, H.M. van Egmond, Renate S. Hagedoorn, Conny Hoogstaten, Sabrina A.J. Veld, Lois Hageman, P. A. G. van Liempt, Jaap Jan Zwaginga, Pauline Meij, Hendrik Veelken, J.H. Frederik Falkenburg, Mirjam H.M. Heemskerk	2020	31
20	Allogeneic HLA-A02–Restricted WT1-Specific T Cells from Mismatched Donors Are Highly Reactive but Show Off-Target Promiscuity The Journal of Immunology* ·Willem J.J. Falkenburg, J. Joseph Melenhorst, Marian van de Meent, Michel G.D. Kester, Pleun Hombrink, Mirjam H.M. Heemskerk, Renate S. Hagedoorn, Emma Gostick, David A. Price, J.H. Frederik Falkenburg, A. John Barrett, Inge Jedema	2011	29

About Inge Jedema

Inge Jedema is a scholar working on Immunology, Hematology, Oncology, Epidemiology and Genetics, having authored 80 papers that have together received 1.9k indexed citations. Recurring topics across this work include T-cell and B-cell Immunology (24 papers), Immune Cell Function and Interaction (24 papers), Hematopoietic Stem Cell Transplantation (23 papers), Immunotherapy and Immune Responses (19 papers), Cytomegalovirus and herpesvirus research (19 papers), CAR-T cell therapy research (12 papers), Virus-based gene therapy research (8 papers) and Acute Myeloid Leukemia Research (5 papers). The work is most often cited by research in Hematology (623 citations), Immunology (922 citations), Oncology (717 citations), Transplantation (29 citations) and Genetics (97 citations). Inge Jedema has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include J.H. Frederik Falkenburg, Roel Willemze, Renée M. Y. Barge, Mirjam H.M. Heemskerk, Michel G.D. Kester, Jacques J. M. van Dongen, Marieke Griffioen, Vincent H. J. van der Velden, Simone A.P. van Luxemburg-Heijs and Nicole M. van der Werff. Their work appears in journals such as Blood, Frontiers in Immunology, Leukemia, Haematologica and Biology of Blood and Marrow Transplantation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Inge Jedema

Impact in

Papers in i

In The Last Decade

Inge Jedema

Peers

Countries citing papers authored by Inge Jedema

Fields of papers citing papers by Inge Jedema

All Works

About Inge Jedema

Explore authors with similar magnitude of impact

Papers in